real peptides FAQ

Administer the missed dose as soon as you remember if fewer than 6 hours have passed since the scheduled time, then resume your regular schedule the following day. If more than 6 hours have elapsed, skip the missed dose entirely and continue with your next scheduled injection. Doubling up doses creates plasma spikes that don't improve mitochondrial protection and may increase the risk of transient hypotension. Missing occasional doses during an 8-week protocol won't negate the entire research cycle, but missing more than 10% of total doses (approximately 11 injections across 56 days) reduces average cardiolipin stabilization below the threshold where VO2 max and inflammatory marker improvements become statistically significant.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your usual injection time, then continue your regular schedule. If more than 12 hours have passed, skip the missed dose entirely and resume the next evening. Do not double-dose to compensate. Missing 1–2 doses during a 10–20 day loading phase delays thymic saturation by approximately 48–72 hours but doesn't negate the protocol's efficacy. Clinical trials measuring CD31+ recent thymic emigrant output found that participants who missed up to 3 non-consecutive doses during loading still achieved 85–90% of the thymic regeneration markers compared to perfect adherence groups.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled time, then resume the normal schedule the following day. If more than 12 hours have passed, skip the missed dose entirely and continue with the next scheduled injection. Do not double-dose to compensate. Missing 1–2 days in a 20-day cycle reduces total peptide exposure by 5–10%, which typically does not negate the cumulative neurotrophic effect, but missing more than 3 days disrupts the BDNF upregulation curve enough that restarting the cycle from day 1 may be necessary to achieve the intended structural outcome.

Discard it and reconstitute a new vial. A peptide left at room temperature for 8–12 hours has experienced significant degradation even if it looks unchanged. Amino acid side chains undergo oxidation, deamidation, and racemisation at temperatures above 15°C. Reactions that accelerate exponentially with time. Using degraded peptide means inconsistent dosing at best and potential immune response to degradation byproducts at worst. There's no salvage protocol that restores potency once thermal degradation has occurred.

No. TB-500's mechanism relies on sustained actin sequestration over time, not peak plasma concentration. Missing one biweekly dose extends the protocol by 3.5 days rather than requiring dose compensation. Doubling the dose doesn't accelerate migration; it increases the peptide circulating without additional target tissue to act upon. Resume your regular schedule and add one extra week to the 28-day protocol.

Verify three variables before concluding the protocol failed: injection timing (should be 30–60 minutes before sleep, not morning), storage compliance (reconstituted thymalin must remain at 2–8°C), and baseline immune status (individuals under 35 with normal thymic function show minimal response because their thymus hasn't undergone significant involution yet). Thymalin's mechanism targets age-related thymic atrophy. If your baseline CD4:CD8 ratio and naive T-cell counts are already optimal, exogenous thymulin won't produce measurable shifts. Clinical responders are typically 45+ with documented thymic involution on imaging or depressed CD31+ RTE counts on flow cytometry.

Particulate formation indicates aggregation from improper storage temperature, contamination during reconstitution, or inherent product instability. Filter the solution through a 0.22-micron sterile syringe filter before use. But understand this is a workaround, not a solution. High-quality tesamorelin stored correctly at 2–8°C should remain clear for the full 28-day shelf life. Persistent particulate formation suggests the original lyophilised product was improperly manufactured or the reconstitution protocol introduced contaminants.

Discard immediately. Epithalon and Thymalin are both supplied as lyophilised powders that should reconstitute into clear, colourless solutions. Cloudiness indicates protein aggregation or bacterial contamination; discolouration suggests oxidative degradation. Both render the peptide biologically inactive and potentially harmful. Proper reconstitution requires bacteriostatic water added slowly down the vial wall (not directly onto the powder), gentle swirling (never shaking), and immediate refrigeration at 2–8°C. Real Peptides includes reconstitution protocols with every shipment specifically to prevent preparation errors that compromise peptide integrity.

Extending beyond 20 days is biologically defensible only in acute stroke or traumatic brain injury contexts where the neuroplastic window remains open and aggressive intervention is warranted. In chronic cognitive enhancement protocols, cycles longer than 30 days trigger Trk receptor downregulation. The neurons become less responsive to the peptide, requiring progressively higher doses to maintain the same BDNF activation. If the goal is sustained neurotrophic support, quarterly 20-day cycles separated by 8-week washouts outperform a single 60-day continuous course in every clinical trial measuring long-term cognitive outcomes.

Resume dosing immediately without attempting to 'catch up' via doubled doses. Neuroplastic adaptation timelines reset partially with each interruption, but the process isn't binary. Missing 2–3 days during the first 14 days delays full adaptation by approximately the same duration (2–3 days), meaning a 14-day protocol with 3 missed doses effectively becomes a 17-day timeline to reach the same endpoint. Consistent daily administration is critical during the initial BDNF upregulation window (days 1–10), while interruptions during weeks 3–4 cause less timeline disruption.

Pause dose escalation and increase caloric intake by 200–300 calories daily, focusing on protein and complex carbohydrates to maintain muscle mass. Weight loss exceeding 1.5% weekly indicates an unsustainable deficit that will trigger metabolic adaptation. Elevated cortisol, suppressed thyroid hormone conversion, and reduced NEAT. Within four to six weeks. The goal is 0.5–1% weekly loss, sustained over months. If increasing intake doesn't slow the rate, consider reducing the current dose by 50% rather than escalating further.

Administer Thymalin first in a 10-day cycle to establish baseline immune restoration, then introduce epithalon in overlapping or sequential cycles. The mechanisms don't interfere. Some institutions run both concurrently with Thymalin administered intramuscularly in the morning and epithalon subcutaneously in the evening to separate injection sites and monitor distinct biomarkers (T-cell counts for Thymalin, telomere length for epithalon). The primary constraint is budget and sample collection frequency. Tracking both immune and cellular aging markers requires more comprehensive testing than single-peptide protocols.

Discard the vial and reconstitute fresh peptide. Room temperature exposure exceeding four hours causes measurable aggregation of the tetrapeptide structure, and there's no reliable at-home method to verify potency after temperature excursion. One overnight mistake doesn't ruin an entire research protocol, but continuing to use compromised peptide means injecting inactive compound for the remainder of that vial's lifespan (potentially 10–14 days at twice-daily dosing). The financial cost of discarding one 50mg vial is significantly lower than the opportunity cost of running a compromised protocol for two weeks and seeing zero biomarker improvement. Our team has reviewed this scenario dozens of times: researchers who continue using temperature-compromised peptide consistently report no measurable change in VO2 max, inflammatory markers, or subjective energy levels.

Discard it. A peptide stored at room temperature (20–25°C) for 8–12 hours undergoes 15–30% potency loss through accelerated hydrolysis and oxidative degradation. There is no visual indicator of this degradation. The solution will appear clear and unchanged, but the peptide backbone has been irreversibly cleaved at multiple amide bonds. Using degraded peptide in research produces low-magnitude or null results that waste experimental resources and animal models. The 28-day stability window assumes continuous refrigeration at 2–8°C. Any temperature excursion above 8°C resets the degradation clock to an accelerated timeframe.

Continue the protocol. Selank's mechanism is receptor upregulation, not direct agonism, meaning the effect builds gradually over 5–7 days. Most researchers report subtle reductions in autonomic arousal (lower resting heart rate, reduced startle response) beginning day 3–4, with full anxiolytic effects apparent by day 7. If you've reached day 10 without any subjective change, verify reconstitution pH and storage temperature. Peptide denaturation during preparation is the most common cause of non-response.

Discard the vial immediately. Clumping indicates aggregation from improper lyophilisation or moisture exposure, and discolouration (yellow or brown tint) signals oxidation. Real Peptides' lyophilised tesamorelin appears as a white to off-white fine powder with no visible clumps. If your batch doesn't match this appearance, contact the supplier for a replacement before reconstituting. Aggregated peptides won't fully dissolve and exhibit significantly reduced receptor binding affinity even if the solution appears clear after mixing.

SS-31's protective effects reverse within 3–4 weeks of discontinuation based on rodent studies. Cardiolipin oxidation resumes, cristae density declines, and ATP output returns toward baseline. This isn't medication failure. It reflects the fact that SS-31 prevents ongoing damage rather than permanently repairing mitochondrial architecture. Researchers planning long-duration studies should incorporate washout periods to assess durability of effects and determine whether benefits persist beyond active treatment.

Telomerase activation is dose- and duration-dependent. Published protocols showing telomere lengthening used 10 mg daily for 20 consecutive days. Shorter cycles or lower doses may activate telomerase without producing measurable telomere length increases within the study timeline. Telomere qPCR also has assay variability of ±5–8%; statistically significant changes require baseline, mid-cycle, and 3-month post-cycle measurements with adequate sample sizes (n≥20 per group). If using a single post-treatment measurement, the signal may fall within assay noise.

Stop and evaluate before injecting. Cloudiness indicates either incomplete dissolution (wait another 5–10 minutes) or aggregation from improper mixing technique. If the solution doesn't clear after 15 minutes at refrigerator temperature, the peptide has likely aggregated. Large peptide clusters that won't dissolve further and shouldn't be injected. Aggregation occurs when bacteriostatic water is added too quickly or sprayed directly onto the lyophilised cake. The vial is unusable. Reconstitute a new vial using the slow wall-drip technique described earlier.

Reduce the dose by 25 mcg per injection immediately and retest fasting glucose in 5–7 days. GHRP-6 elevates cortisol, which drives hepatic gluconeogenesis. Sustained hyperglycemia signals the cortisol response is exceeding the patient's metabolic clearance capacity. In patients over 60, this happens at doses that younger adults tolerate without glucose changes because age-related insulin resistance compounds the effect. If glucose remains elevated after dose reduction, discontinue GHRP-6 and consider alternative GH secretagogues with lower cortisol impact.